High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring <i>MUC16</i>/CA125 mutations.

Aging (Albany NY) · 2020 · PMC7346065 · PMID 32491995

Europe PMC DOI

hedged sentence

0.0910

closest p · 1.8× alpha

0.0910

boldest claim

The sentences

did not reach statistical significanceP = 0.091so close (0.05 < p ≤ 0.1)

Male patients with MUC16 mutations exhibited a better trend of progression-free survival (PFS) than those without MUC16 mutations although this difference did not reach statistical significance (median PFS: 9.07 [95% CI, 3.60-25.1] vs. 3.03 [95% CI, 2.57-8.00] months; Log rank test P = 0.091; Figure 5G ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.